title: Insulin treatment promotes tyrosine phosphorylation of PKR and inhibits polyIC induced PKR threonine phosphorylation.
abstract: Tyrosine phosphorylation of insulin receptor beta (IRβ) in insulin treated HepG2 cells is inversely correlated to ser(51) phosphorylation in the alpha-subunit of eukaryotic initiation factor 2 (eIF2α) that regulates protein synthesis. Insulin stimulates interaction between IRβ and PKR, double stranded RNA-dependent protein kinase, also known as EIF2AK2, and phosphorylation of tyrosine residues in PKR, as analyzed by immunoprecipitation and pull down assays using anti-IRβ and anti-phosphotyrosine antibodies, recombinant IRβ and immunopurified PKR. Further polyIC or synthetic double stranded RNA-induced threonine phosphorylation or activation of immunopurified and cellular PKR is suppressed in the presence of insulin treated purified IRβ and cell extracts. Acute, but not chronic, insulin treatment enhances tyrosine phosphorylation of IRβ, its interaction with PKR and tyrosine phosphorylation of PKR. In contrast, lipopolysaccharide that stimulates threonine phosphorylation of PKR and eIF2α phosphorylation and AG 1024, an inhibitor of the tyrosine kinase activity of IRβ, reduces PKR association with the receptor, IRβ in HepG2 cells. These findings therefore may suggest that tyrosine phosphorylated PKR plays a role in the regulation of insulin induced protein synthesis and in maintaining insulin sensitivity, whereas, suppression of polyIC-mediated threonine phosphorylation of PKR by insulin compromises its ability to fight against virus infection in host cells.
authors: Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500 046, Telangana, India.
authors: Medchalmi
authors: M
authors: Swetha
authors: Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500 046, Telangana, India. Electronic address: kvarsl@uohyd.ernet.in.
authors: Kolluru V A
authors: KVA
authors: Ramaiah
mesh_terms: D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D015852:Eukaryotic Initiation Factor-2 / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation; D056945:Hep G2 Cells; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D010766:Phosphorylation; D011070:Poly I-C / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014176:Protein Biosynthesis; D012330:RNA, Double-Stranded / Q000494:pharmacology; D011972:Receptor, Insulin / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013912:Threonine / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism*; D020032:Tyrphostins / Q000494:pharmacology; D019892:eIF-2 Kinase / Q000235:genetics / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D015852:Eukaryotic Initiation Factor-2; D007328:Insulin; D008070:Lipopolysaccharides; D012330:RNA, Double-Stranded; D020032:Tyrphostins; C447031:tyrphostin AG 1024; D013912:Threonine; D014443:Tyrosine; C435941:INSR protein, human; D011972:Receptor, Insulin; C583541:EIF2AK1 protein, human; D019892:eIF-2 Kinase; D011070:Poly I-C
keywords: Eukaryotic initiation factor 2; HepG2 cells; Insulin receptor; Insulin sensitivity and resistance; RNA-dependent protein kinase; Tyrosine and threonine phosphorylation